Login / Signup

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice.

Kai WuAngela ChoiMatthew KochSayda ElbashirLingZhi MaDiana LeeAngela WoodsCarole HenryCharis PalandjianAnna HillHardik JaniJulian QuinonesNaveen NunnaSarah Oâ ConnellAdrian B McDermottSamantha FalconeElisabeth NarayananTonya ColpittsHamilton BennettKizzmekia S CorbettRobert SederBarney S GrahamGuillaume Be Stewart-JonesAndrea CarfiDarin K Edwards
Published in: bioRxiv : the preprint server for biology (2021)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic that has led to more than 2.8 million deaths worldwide. Safe and effective vaccines are now available, including Moderna's COVID-19 vaccine (mRNA-1273) that showed 94% efficacy in prevention of symptomatic COVID-19 disease in a phase 3 clinical study. mRNA-1273 encodes for a prefusion stabilized full length spike (S) protein of the Wuhan-Hu-1 isolate. However, the emergence of SARS-CoV-2 variants has led to concerns of viral escape from vaccine-induced immunity. Several emerging variants have shown decreased susceptibility to neutralization by vaccine induced immunity, most notably the B.1.351 variant, although the overall impact on vaccine efficacy remains to be determined. Here, we present the initial evaluation in mice of two updated COVID-19 mRNA vaccines designed to target emerging SARS-CoV-2 variants: (1) monovalent mRNA-1273.351 encodes for the S protein found in the B.1.351 lineage and (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351. Both vaccines were evaluated as a 2-dose primary series in mice; mRNA-1273.351 was also evaluated as a booster dose in animals previously vaccinated with 2-doses of mRNA-1273. The results demonstrated that a primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against the B.1.351 lineage, while mRNA-1273.211 was most effective at providing broad cross-variant neutralization in mice. In addition, these results demonstrated a third dose of mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers. Both mRNA-1273.351 and mRNA-1273.211 are currently being evaluated in additional pre-clinical challenge models and in phase 1/2 clinical studies.
Keyphrases
  • sars cov
  • respiratory syndrome coronavirus
  • binding protein
  • coronavirus disease
  • type diabetes
  • zika virus
  • skeletal muscle
  • adipose tissue
  • dengue virus